Drug Trial Radar · NCT07694544
Renal Impairment Study for Oral EC5026
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- EicOsis Human Health Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this Phase 1 clinical trial is to assess single dose pharmacokinetics of oral EC5026 in a population with chronic kidney disease. The main questions it aims to answer are: 1. To determine if the PK of a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD differs from age-matched healthy participants with normal kidney function. 2. To determine if a single 8 mg dose of EC5026, administered orally, in adult participants with varying severity of CKD is safe and well tolerated. Researchers will compare a single 8 mg dose of oral across participants with varying degrees of kidney function impairment (either normal kidney function, or stage 3b chronic kidney disease \[CKD\], or state 4/5 CKD). Participants will be asked to take a single oral dose of EC5026 and will be monitored with PK laboratory assessments and safety assessments (including physical exams, vital signs, electrocardiograms, and others).
Conditions
- Chronic Kidney Disease
Interventions
EC5026 oral tabletDrug
Oral 8 mg EC5026 tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC0-t)Time frame: 14 days
- Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC0-∞)Time frame: 14 days
- Maximum observed plasma concentration (Cmax)Time frame: 14 days
- Time to the maximum observed concentration of the drug (Tmax)Time frame: 14 days
- Apparent terminal elimination rate constant (Kel)Time frame: 14 days
- Terminal elimination half-life of the drug (t½).Time frame: 14 days
- Apparent clearance (CL/F).Time frame: 14 days
- Apparent volume of distribution during the terminal phase (Vz/F)Time frame: 14 days
- Renal clearance (CLR)Time frame: 48 hours
- Amount of unchanged drug excreted in urine (Ae).Time frame: 48 hours
- Fraction of eliminated dose (Fe%)Time frame: 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UC Davis Medical Center
Sacramento, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.